Chronic obstructive pulmonary disease exacerbation resident survival guide

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Definition

  • An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.[1][2][3]
  • The diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.[4]

Causes

Life Threatening Causes

Include conditions which may result death or permanent disability within 24 hours if left untreated, and some of them may mimic and/or aggravate exacerbations:

Common Causes

Differential Diagnosis

Management

COPD Exacerbation
❑ Cough ↑
❑ Dyspnea ↑
❑ Sputum ↑
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Oxygen Supplement
❑ Pulse oximetry (maintain SaO2 ≥88—92%)[5]
❑ Arterial blood gas (if acute or acute-on-chronic respiratory failure is suspected)


Indications for ICU Admission
❑ Hemodynamic instability
❑ Changes in mental status (confusion, lethargy, coma)
❑ Severe dyspnea that responds inadequately to initial emergency therapy
❑ Worsening hypoxemia (PaO2 <40 mm Hg) and/or respiratory acidosis (pH <7.25)


Indications for Hospitalization
❑ Marked increase in intensity of symptoms (eg, sudden development of resting dyspnea)
❑ Severe underlying COPD (GOLD 3—4 categories)
❑ Onset of new physical signs (eg, cyanosis, peripheral edema)
❑ Failure of an exacerbation to respond to initial medical management
❑ Presence of serious comorbidities (eg, heart failure or newly occurring arrhythmias)
❑ Frequent exacerbations (≥2 events per year)
❑ Older age (>65 years)
❑ Insufficient home support


Assessment of Severity of Exacerbation
❑ Chest radiograph (exclude alternative diagnoses)
❑ ECG (check coexisting cardiac problems)
❑ Whole-blood count (identify polycythemia, anemia, or leukocytosis)
❑ Electrolytes and glucose (identify electrolyte disturbances or hyperglycemia)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
123
 
 




PaO2 <60 mm Hg with or without PaCO2 >50 mm Hg in ambient air



 
 
 
COPD Exacerbation
cough, ↑dyspnea, ↑sputum,
wheezing, fever or chest tightness
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Admission
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment :
1-O2 sat+ ABG
2-CXR
3-EKG
4-CBC


Management:
1-Inhaled bronchodilators
2-Systemic corticosteroids
3-Empirical antibiotics
4-O2 (target Sat >90%)
 
Corticosteroids(Solumedrol)
Methylprednisolone 125 mg×1 dose
followed with 60-80 mg Q8-12based on severity
IV Solumedrol to PO Prednisone taper 4--60 mg Q 8-12
2-5 days taper depending on severity
Antibiotics
Group A*
Doxycycline Cap Vibramycin PO 100 mg Q12H
(if unable to tolerate choose Cefpodoxime Tab Vantin PO 200 mg Q12H)
Group B*
Ceftriaxone Inj Rocephin 1GM D5W50 ml Q24H 200 ml/Hr
(If Beta-Lactam allergy choose Levofloxacin Tab Levaquin PO 500 mg daily )
Group C*
Ciprofloxacin Tab CiproPO 250 Daily
or Ciprofloxacin Inj Cipro 400 mg premixed at 400 mg /200 ml Q12H 200 ml/Hr.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respiratory acidosis? OR
PH≤35? OR
PaCo2≥45? OR
Severe signs of dyspnea? OR
Accessory muscles use,
paradoxical motion of abdomen,
retraction of intercostal space
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
Yes
 
 
 
 
 
 
 
 
 
 
Continue the same management
 
 
ICU Admission
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-invasive ventilation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unable to tolerate NIV?
Severe hemodynamic instability?
Resp/cardiac arrest ?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Invasive mechanical ventilation
 

Do's

  • Monitor fluid balance,nutrition and patient condition closely.
  • Consider subcutaneous heparin or low molecular weight heparin.
  • Treat associated conditions if exist(e.g., heart failure,arrhythmias).

Don'ts

  • Spirometry is not recommended during an exacerbation because it can be difficult to perform and measurements are not accurate enough.

References

  1. Burge, S.; Wedzicha, JA. (2003). "COPD exacerbations: definitions and classifications". Eur Respir J Suppl. 41: 46s–53s. PMID 12795331. Unknown parameter |month= ignored (help)
  2. Celli, BR.; Barnes, PJ. (2007). "Exacerbations of chronic obstructive pulmonary disease". Eur Respir J. 29 (6): 1224–38. doi:10.1183/09031936.00109906. PMID 17540785. Unknown parameter |month= ignored (help)
  3. Rodriguez-Roisin, R. (2000). "Toward a consensus definition for COPD exacerbations". Chest. 117 (5 Suppl 2): 398S–401S. PMID 10843984. Unknown parameter |month= ignored (help)
  4. Vestbo, J.; Hurd, SS.; Agustí, AG.; Jones, PW.; Vogelmeier, C.; Anzueto, A.; Barnes, PJ.; Fabbri, LM.; Martinez, FJ. (2013). "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary". Am J Respir Crit Care Med. 187 (4): 347–65. doi:10.1164/rccm.201204-0596PP. PMID 22878278. Unknown parameter |month= ignored (help)
  5. Austin, MA.; Wills, KE.; Blizzard, L.; Walters, EH.; Wood-Baker, R. (2010). "Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial". BMJ. 341: c5462. PMID 20959284.